Speakers

Riccardo Belli

Riccardo Belli

Director, Novartis Oncology (Switzerland)

Riccardo Belli joined in Novartis Oncology on March 2018. He has more than 10 years experience in pharmaceutical clinical development matured in different companies and attending at ECPM (European course of pharmaceutical medicine) course in Basel (Switzerland) with track record of publications in immunology and immunooncology. He gradued in medicine at university of Chieti (Italy) with international postdegree fellowship as DAAD guest at Charite klinik Humboldt university of Berlin (Germany) where he was involved in the study and characterization of Natural killer immunophenotype in advanced cancer patients. Experience in immunology and immunooncology further continued at Molmed Spa in Milan (Italy) with involvement of development of immunocytokine and adoptive gene suicide immunotherapy and in AstraZeneca as part of the global immononcology team for the development of durvalumab and tremelimumab combinations.